Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [1] Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer
    Leiming Zhang
    Zehao Yu
    Rong Jin
    Xuanang Yang
    Dongjian Ying
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 11857 - 11871
  • [2] The surgical outcomes of borderline resectable or locally advanced pancreatic cancer
    Okamura, Yukiyasu
    Sugiura, Teiichi
    Ito, Takaaki
    Yamamoto, Yusuke
    Ashida, Ryo
    Ohgi, Katsuhisa
    Uesaka, Katsuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection
    Tamburrino, Domenico
    De Stefano, Federico
    Belfiori, Giulio
    Partelli, Stefano
    Crippa, Stefano
    Falconi, Massimo
    JOURNAL OF GASTROINTESTINAL SURGERY, 2023, 27 (12) : 3014 - 3023
  • [4] Surgical Planning for “Borderline Resectable” and “Locally Advanced” Pancreatic Cancer During Open Pancreatic Resection
    Domenico Tamburrino
    Federico De Stefano
    Giulio Belfiori
    Stefano Partelli
    Stefano Crippa
    Massimo Falconi
    Journal of Gastrointestinal Surgery, 2023, 27 : 3014 - 3023
  • [5] Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
    Kovtun, K.
    Moser, J. A.
    Callery, M.
    Kent, T.
    Tseng, J.
    Miksad, R.
    Bullock, A.
    Schlechter, B.
    Mahadevan, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E198 - E198
  • [6] Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?
    Daniel M. Halperin
    Gauri R. Varadhachary
    Current Oncology Reports, 2014, 16
  • [7] Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?
    Halperin, Daniel M.
    Varadhachary, Gauri R.
    CURRENT ONCOLOGY REPORTS, 2014, 16 (02)
  • [8] Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer
    Karamarkovic, Aleksandar R.
    Juloski, Jovan T.
    CHIRURGIA, 2022, 117 (04) : 385 - 398
  • [9] Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer
    Del Chiaro, Marco
    Valente, Roberto
    Arnelo, Urban
    JAMA SURGERY, 2017, 152 (11) : 1057 - 1057
  • [10] Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer
    Kjetil S?reide
    Hepatobiliary & Pancreatic Diseases International, 2022, 21 (03) : 205 - 206